GlassScriptPhysician profile
Willie Adams
NPI 1194971242
$1,319.71
in general payments reported to CMS, 2019-2025
14 companies · $73.46 in 2025
The $73.46 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $294 · 2023: $493 · 2024: $154 · 2025: $73.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $587.81 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $159.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $97.12 | 2021-2023 | Pediarix, Bexsero, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $84.70 | 2021-2023 | |
| Exact Sciences Corporation | $80.47 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $70.33 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $63.74 | 2023 | Hetlioz |
| Abbott Laboratories | $46.66 | 2021-2022 | |
| Amgen INC. | $39.55 | 2023-2024 | Repatha, Otezla |
| Paratek Pharmaceuticals, INC. | $23.46 | 2022 | |
| Merck Sharp & Dohme LLC | $21.48 | 2023 | Delstrigo, Isentress, Pifeltro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.01 | 2023 | Synjardy |
| Dexcom, INC. | $15.72 | 2023 | Dexcom G6 Transmitter |
| Phadia US INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willie Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.